Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,037 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Chen Y, Wyatt D, Attanasio M, Thomas M, Thomas M, He B, Nishii R, Liu L, Shan V, Xue Y, Carayannopoulos LN, Ogasawara K, Krishna G. Chen Y, et al. Among authors: thomas m. Cancer Chemother Pharmacol. 2024 Apr;93(4):307-317. doi: 10.1007/s00280-023-04612-w. Epub 2023 Nov 13. Cancer Chemother Pharmacol. 2024. PMID: 37955741 Free PMC article. Clinical Trial.
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y, Gaudy A, Schafer P, Thomas M, Weiss D, Chen N, Liu L, Xue Y, Carayannopoulos L, Palmisano M. Ye Y, et al. Among authors: thomas m. Clin Pharmacol Drug Dev. 2021 May;10(5):471-485. doi: 10.1002/cpdd.869. Epub 2020 Sep 23. Clin Pharmacol Drug Dev. 2021. PMID: 32969202 Free PMC article. Clinical Trial.
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G. Chen Y, et al. Among authors: thomas m. Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w. Epub 2022 Aug 24. Cancer Chemother Pharmacol. 2022. PMID: 36001108 Free PMC article.
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, Liu L, Chen J, Ghosh A, Carayannopoulos LN, Tatosian DA, Palmisano M. Ye Y, et al. Among authors: thomas m. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1394-1404. doi: 10.1002/cpdd.1178. Epub 2022 Oct 18. Clin Pharmacol Drug Dev. 2022. PMID: 36256505 Free PMC article. Clinical Trial.
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH, Ye Y, Wu L, Kosek J, Ringheim G, Yang Z, Liu L, Thomas M, Palmisano M, Chopra R. Schafer PH, et al. Among authors: thomas m. Ann Rheum Dis. 2018 Oct;77(10):1516-1523. doi: 10.1136/annrheumdis-2017-212916. Epub 2018 Jun 26. Ann Rheum Dis. 2018. PMID: 29945920 Free PMC article. Clinical Trial.
11,037 results
You have reached the last available page of results. Please see the User Guide for more information.